Total Payments
$1,002
2024 Payments
$29.96
Companies
10
Transactions
55
Medicare Patients
5,854
Medicare Billing
$855,654
Payment Breakdown by Category
Food & Beverage$1,001 (99.9%)
Education$0.79 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,001 | 54 | 99.9% |
| Education | $0.79 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $335.83 | 33 | $0 (2021) |
| Novo Nordisk Inc | $318.13 | 7 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $111.85 | 1 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $106.65 | 4 | $0 (2024) |
| Amgen Inc. | $46.29 | 3 | $0 (2024) |
| Allergan Inc. | $22.61 | 2 | $0 (2017) |
| AbbVie, Inc. | $22.28 | 1 | $0 (2018) |
| Celgene Corporation | $21.51 | 2 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29.96 | 2 | Amgen Inc. ($15.45) |
| 2023 | $143.48 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($111.85) |
| 2022 | $214.30 | 4 | Novo Nordisk Inc ($122.16) |
| 2021 | $136.85 | 2 | Novo Nordisk Inc ($112.69) |
| 2020 | $144.50 | 8 | PFIZER INC. ($75.15) |
| 2019 | $46.61 | 3 | PFIZER INC. ($46.61) |
| 2018 | $226.11 | 27 | PFIZER INC. ($163.58) |
| 2017 | $59.84 | 5 | PFIZER INC. ($26.33) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Cardiology | ||||||
| 01/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Cardio-renal | ||||||
| 10/10/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Inflammation | ||||||
| 08/01/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $111.85 | General |
| Category: DIABETES | ||||||
| 02/15/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: Cardiology | ||||||
| 01/20/2023 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Education | In-kind items and services | $0.79 | General |
| Category: UROLOGY | ||||||
| 08/17/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.12 | General |
| Category: Cardio-renal | ||||||
| 06/21/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $122.16 | General |
| Category: Diabetes | ||||||
| 03/17/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $32.67 | General |
| Category: Cardio-renal | ||||||
| 01/20/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $34.35 | General |
| Category: Cardio-renal | ||||||
| 06/08/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $112.69 | General |
| Category: Diabetes | ||||||
| 05/19/2021 | PFIZER INC. | COLOGUARD DNA CAPTURE REAGENTS (Device) | Food and Beverage | In-kind items and services | $24.16 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/10/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $30.43 | General |
| Category: GASTROINTESTINAL | ||||||
| 10/01/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Diabetes | ||||||
| 09/02/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: GASTROINTESTINAL | ||||||
| 09/01/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Diabetes | ||||||
| 06/29/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Diabetes | ||||||
| 06/23/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $11.45 | General |
| Category: GASTROINTESTINAL | ||||||
| 04/28/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS, Tresiba | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Diabetes | ||||||
| 01/31/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/19/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: GASTROINTESTINAL | ||||||
| 10/24/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: GASTROINTESTINAL | ||||||
| 08/15/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/20/2018 | PFIZER INC. | LYRICA (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $1.03 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
| 11/13/2018 | PFIZER INC. | LYRICA (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $1.49 | General |
| Category: NEUROSCIENCE;PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 953 | 2,308 | $294,018 | $148,978 |
| 2022 | 24 | 1,292 | 2,959 | $327,689 | $184,055 |
| 2021 | 28 | 1,571 | 3,541 | $401,829 | $237,941 |
| 2020 | 33 | 2,038 | 4,553 | $493,695 | $284,681 |
Total Patients
5,854
Total Services
13,361
Medicare Billing
$855,654
Procedure Codes
107
All Medicare Procedures & Services
107 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 186 | 728 | $134,250 | $59,992 | 44.7% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 50 | 291 | $29,009 | $17,722 | 61.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 114 | 114 | $20,862 | $13,846 | 66.4% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 49 | 229 | $24,961 | $12,809 | 51.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 111 | 171 | $22,291 | $9,873 | 44.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 72 | 163 | $14,797 | $9,181 | 62.0% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Office | 2023 | 41 | 41 | $10,947 | $5,716 | 52.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 15 | 20 | $7,980 | $4,176 | 52.3% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 22 | 33 | $5,148 | $2,683 | 52.1% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Office | 2023 | 23 | 27 | $5,265 | $2,653 | 50.4% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 16 | 35 | $5,030 | $2,422 | 48.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 24 | 24 | $2,903 | $1,979 | 68.2% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 33 | 38 | $2,320 | $1,541 | 66.4% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Office | 2023 | 16 | 44 | $2,552 | $1,236 | 48.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 21 | 21 | $2,034 | $1,210 | 59.5% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 24 | 50 | $1,250 | $811.00 | 64.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 37 | 75 | $1,570 | $742.70 | 47.3% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 38 | 49 | $292.00 | $193.06 | 66.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 13 | 14 | $332.00 | $130.80 | 39.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 17 | 49 | $189.00 | $54.62 | 28.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 13 | 71 | $29.16 | $6.43 | 22.1% |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | Office | 2023 | 18 | 21 | $6.56 | $0.40 | 6.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 216 | 796 | $139,310 | $64,354 | 46.2% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 126 | 426 | $32,664 | $21,845 | 66.9% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 58 | 335 | $33,500 | $20,557 | 61.4% |
About Dr. Mohammad Kalo, M.D
Dr. Mohammad Kalo, M.D is a Internal Medicine healthcare provider based in Wheelersburg, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750305538.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammad Kalo, M.D has received a total of $1,002 in payments from pharmaceutical and medical device companies, with $29.96 received in 2024. These payments were reported across 55 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($1,001).
As a Medicare-enrolled provider, Kalo has provided services to 5,854 Medicare beneficiaries, totaling 13,361 services with total Medicare billing of $855,654. Data is available for 4 years (2020–2023), covering 107 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Wheelersburg, OH
- Active Since 07/26/2006
- Last Updated 02/20/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1750305538
Products in Payments
- LYRICA (Drug) $176.00
- Rybelsus (Drug) $122.16
- COLOGUARD (Device) $121.76
- RYBELSUS (Drug) $112.69
- JARDIANCE (Drug) $111.85
- Kerendia (Drug) $106.65
- Ozempic (Drug) $69.35
- Otezla (Drug) $36.89
- Repatha (Biological) $30.91
- COLOGUARD DNA CAPTURE REAGENTS (Device) $24.16
- RELISTOR (Drug) $15.71
- Victoza (Drug) $13.93
- EMBEDA (Drug) $13.91
- LINZESS (Drug) $11.98
- NAMZARIC (Drug) $10.63
- GEMTESA (Drug) $0.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.